Breast cancer metastatic+2
Not recruitingStudy of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer
Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer
- Disease:Breast cancer metastaticTriple negative breast cancer+1
- Substances:CarboplatinDurvalumab+2
Belgium- Participants:18–64 years
- Substances:Carboplatin
- Sponsor:Institut Jules Bordet










